AstraZeneca PLC $AZN Shares Bought by RWA Wealth Partners LLC

Key Points

• RWA Wealth Partners LLC increased its holdings in AstraZeneca PLC by 35.2%, acquiring an additional 13,314 shares to own a total of 51,147 shares valued at approximately $3.76 million.
• AstraZeneca recently reported quarterly earnings of $1.09 per share, matching analysts' expectations, with revenue of $14.46 billion, surpassing predictions of $14.08 billion.
• The company announced a semi-annual dividend of $0.505 per share, with a payout ratio of 37.97%, signaling a commitment to returning value to shareholders despite a recent cut in dividend payments.

RWA Wealth Partners LLC boosted its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 35.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 51,147 shares of the company's stock after acquiring an additional 13,314 shares during the period. RWA Wealth Partners LLC's holdings in AstraZeneca were worth $3,759,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the business. Lindbrook Capital LLC grew its stake in AstraZeneca by 1.9% in the 1st quarter. Lindbrook Capital LLC now owns 7,574 shares of the company's stock valued at $557,000 after acquiring an additional 141 shares during the last quarter. Principal Securities Inc. raised its stake in AstraZeneca by 0.5% in the 1st quarter. Principal Securities Inc. now owns 28,053 shares of the company's stock valued at $2,062,000 after purchasing an additional 142 shares during the last quarter. Sage Mountain Advisors LLC raised its stake in AstraZeneca by 3.4% in the 1st quarter. Sage Mountain Advisors LLC now owns 4,478 shares of the company's stock valued at $329,000 after purchasing an additional 147 shares during the last quarter. CoreCap Advisors LLC raised its stake in AstraZeneca by 31.8% in the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock valued at $42,000 after purchasing an additional 155 shares during the last quarter. Finally, Oakworth Capital Inc. raised its stake in AstraZeneca by 2.0% in the 1st quarter. Oakworth Capital Inc. now owns 8,575 shares of the company's stock valued at $630,000 after purchasing an additional 167 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank set a $97.00 target price on shares of AstraZeneca in a research note on Wednesday, July 9th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $86.00.

AstraZeneca Trading Up 0.6%

NASDAQ:AZN traded up $0.51 during mid-day trading on Friday, reaching $80.97. The company's stock had a trading volume of 3,603,793 shares, compared to its average volume of 5,450,153. The company's fifty day simple moving average is $72.93 and its two-hundred day simple moving average is $72.24. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68. The stock has a market cap of $251.12 billion, a P/E ratio of 30.44, a P/E/G ratio of 1.48 and a beta of 0.36.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.09. The firm had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The firm's quarterly revenue was up 16.1% on a year-over-year basis. During the same period last year, the company earned $1.24 EPS. On average, equities analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Cuts Dividend

The company also recently declared a semi-annual dividend, which will be paid on Monday, September 8th. Shareholders of record on Friday, August 8th will be paid a dividend of $0.505 per share. The ex-dividend date is Friday, August 8th. This represents a yield of 200.0%. AstraZeneca's dividend payout ratio is currently 37.97%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.